Pharmacyclics Reports Results for Six and Three Months Ended Decembe... (he Company from Janssen under the collab...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012

Date:2/14/2013

he Company from Janssen under the collaboration and license agreement.Pharmacyclics, Inc.
Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data) Three Months EndedSix Months EndedDec. 31,Sep. 30,Dec. 31,Dec. 31, Dec. 31,20122012201120122011Revenue: License and milestone revenue

$ 55,000$ 100,000$ 77,605$ 155,000$ 77,605 Collaboration services revenue

2,9632,6952985,658335Total revenue

57,963102,69577,903160,65877,940Operating expenses*: Research and Development

27,56719,07212,07646,63923,324 Less: Excess amounts related to Research and Development

(17,306)--(17,306)-Research and Development, net

10,26119,07212,07629,33323,324 General and Administrative

7,2254,8683,94412,0937,294 Less: Excess amounts related to General and Administrative

(819)--(819)-General and Administrative, net

6,4064,8683,94411,2747,294Total operating expenses

16,66723,94016,02040,60730,618Income from operations

41,29678,75561,883120,05147,322Interest and other income, net

77522112944Income before income taxes

41,37378,80761,904120,18047,366Income tax benefit (provision)

554(3,201)(5,651)(2,647)(5,651)Net income

$ 41,927$ 75,606$ 56,253$ 117,533$ 41,715Net income per share:Basic

$
.60$
.09$
.82$
.69$
.61Diluted

$
.56$
.02$
.78$
.58$
.58Weighted average shares used to computenet income per share:Basic

69,83969,51268,65869,67668,491Diluted

74,39974,45671,72574,40871,312* Includes share-based compensation as follows:Research and development

$ 2,767$
2,590$ 1,701$
5,357$
3,239General and administrative

1,5035766752,0791,301$ 4,270$
3,166$ 2,376$
7,436$
4,540Reconciliation of Selected GAAP Measures to Non-GAAP Measures ⁽¹⁾ '/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies

Post Your Comments:

(Date:5/16/2013)... 16, 2013 As the weather warms, women ... favorite Spring looks. While most make a statement with fashion, ... women find the warmer weather mixes makeup and sweat to ... the onset of acne during warmer months, Adult Acne ... treatment users the best ways to deter breakouts. , ...

(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Competitor Analysis: Therapeutic Proteins ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ... The new Competitive ...

(Date:5/16/2013)... Arlington, VA (PRWEB) May 16, 2013 ... for Primary Cells & Stem Cell-Derived Cells: Current and ... low, the number of suppliers in the primary cells ... examines what cell types are used most often, how ... is the market size and anticipated growth rate. ...

(Date:5/16/2013)... Stephen Y. Chou, Founder of Nanonex Corporation, will be ... IEEE Nano 2013 in Beijing, China, on August 5th ... becoming one of the most critical nanofabrication technologies today ... large area, and low cost unmatchable by other nanofabrication ... a broad range of industries, from ICs, nano/micro optical ...

Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8 BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2 BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3 Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2

[0] Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup [0] Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors [0] BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)[0] Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013

... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today ... month period ended March 31, 2008., "We ... total of nine,clinical trials, four exploring the use ... use of REOLYSIN(R) in combination with a variety ...

... Squibb,Company (NYSE: BMY ) invites investors and the ... meeting with stockholders at 10 a.m. ET on Tuesday,May ... items to be,transacted, senior executives will review the status ... listen to the webcast, please visit the,Investor Relations page ...

... Training Institute joins the SURGEX(TM) Team, ... Inc., wholly-owned subsidiary of Millennium Biotechnologies,Group, Inc. ... SURGEX(TM) has,become the official sports nutrition drink ... Florida,s premier basketball training facility for,NBA stars ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results Bristol-Myers Squibb Invites Public to Listen to Webcast of 2008 Annual Meeting SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility

(Date:5/18/2013)... Orlando, FL (May 18, 2013) An increasing ... that require interventions to resolve, according to research ... In one study targeting obesity, researchers at the ... have a unique pattern of exhaled breath compared ... in volatile organic compound levels that can be ...

(Date:5/17/2013)... of New Jersey, and City University of New York ... that effectively clears organisms to be viewed under ... hydrate, which is one of the few high-quality clearing ... the Drug Enforcement Administration (DEA) due to its use ... are vital for viewing organisms under a microscope. Without ...

(Date:5/17/2013)... 17, 2013, Shenzhen, China---- Why Tibetan antelope can ... Plateau? In a collaborative research published in ... and other institutes provide evidence that some genetic ... to harsh highland environments. The data in this ... genetic mechanisms and the biology of other ruminant ...

Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2 New research identifies risks, interventions for children's GI health 3 New formula invented for microscope viewing, substitutes for federally controlled drug 2 New formula invented for microscope viewing, substitutes for federally controlled drug 3 The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2

[0] New research identifies risks, interventions for children's GI health [0] New formula invented for microscope viewing, substitutes for federally controlled drug [0] The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation

... 15, 2012 ChromaDex Corporation (OTCBB: CDXC) an ... solutions and ingredients to the dietary supplement, food ... financial results for the fiscal year ended December ... accordance with United States Generally Accepted Accounting Principles ...

... , , , , , , ... , , AUDIO: This ... , Click here for more information. , ... , , , , ...

... with conservation tillage increases, more growers are encountering slugs, ... virtually all crops, and they are challenging to control ... are available. In "Slug (Mollusca: Agriolimacidae, Arionidae) Ecology ... on the mid-Atlantic Region," a free, open-access article appearing ...

Cached Biology News:ChromaDex® Announces Financial Results for the Year Ended 2011 2 ChromaDex® Announces Financial Results for the Year Ended 2011 3 ChromaDex® Announces Financial Results for the Year Ended 2011 4 ChromaDex® Announces Financial Results for the Year Ended 2011 5 Common North American frog identified as carrier of deadly amphibian disease 2 Common North American frog identified as carrier of deadly amphibian disease 3 Common North American frog identified as carrier of deadly amphibian disease 4

ChromaDex® Announces Financial Results for the Year Ended 2011 Common North American frog identified as carrier of deadly amphibian disease Slug ecology and management in no-till field crops

... stored within neurons in vesicles called ... the synaptic bouton. Synaptosomes may ... from other cellular debris. Abnormalites in ... many pathological condtions. Conditions of ...

... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...

... of your microarray data using Asuragens ... you need from consultation to extensive ... to date methods. Utilize our expertise ... Profiling Service or from your own ...

... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...

Biology Products:

Superfusion System, Raiteri's Method from myNeuroLab.com Corning Roller Bottle Easy Grip Caps, Sterile from Sigma-Aldrich Affymetrix Standard Data Analysis Report from Asuragen, Inc.CORNING ROLLER BOTTLE, 850CM2, PS, EASY GRIP CAP, GRADUATED from Sigma-Aldrich